Top-News

Hemispherx Biopharma News

Aktie
WKN:  A2AQ0P ISIN:  US42366C3016 US-Symbol:  HEB
Keine aktuellen Kursdaten verfügbar
Handeln Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Aktienanzahl *
47,25 Mio.
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 27.09.2018

Hemispherx Biopharma News

08.05.23 - PR Newswire
TMX Group Equity Financing Statistics - April 2023
TMX Group Equity Financing Statistics - April 2023 Canada NewsWire
06.11.17 - PR Newswire
Hemispherx Biopharma, Inc. Presentation Now Available for On-Demand Viewing
Hemispherx Biopharma, Inc. Presentation Now Available for On-Demand Viewing Company invites individual and institutional investors as well as advisors to log-on to ...
30.10.17 - PR Newswire
Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present November 2nd
Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present November 2nd PR Newswire
30.10.17 - PR Newswire
Hemispherx Biopharma, Inc. to Webcast, Live, at VirtualInvestorConferences.com November 2
Hemispherx Biopharma, Inc. to Webcast, Live, at VirtualInvestorConferences.com November 2 PR Newswire
25.08.16 - GlobeNewswire
Hemispherx Biopharma gibt einen bedeutsamen Durchbruch bekannt: die Zulassung zur Vermarktung von Rintatolimod (US-Handelsname: Ampligen®) für die Behandlung schwerer Fälle der Myalgischen Enzephal...
Hemispherx Biopharma gibt einen bedeutsamen Durchbruch bekannt: die Zulassung zur Vermarktung von Rintatolimod (US-​Handelsname: Ampligen®) für die Behandlung ...
24.08.16 - GlobeNewswire
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod... Hemispherx Biopharma Announces Major Breakthrough: Approval for ...
23.01.13 - PR Newswire
Pittsburgh Law Office of Alfred G. Yates Jr., P.C. Files Class Action Lawsuit On Behalf of Shareholders of Groupon (GRPN) and Announces Investigations of Diodes (DIOD), Hemispherex Biopharma (HEB), IS
Pittsburgh Law Office of Alfred G. Yates Jr., P.C. Files Class Action Lawsuit On Behalf of Shareholders of Groupon (GRPN) and Announces Investigations of Diodes (DIOD), ...
18.01.13 - PR Newswire
Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc. PR Newswire
29.12.12 - PR Newswire
Faruqi & Faruqi, LLP Encourages Investors Who Suffered $50,000 or More In Losses Investing In Hemispherx Biopharma, Inc. To Contact The Firm
Faruqi & Faruqi, LLP Encourages Investors Who Suffered $50,000 or More In Losses Investing In Hemispherx Biopharma, Inc. To Contact The Firm PR Newswire
29.12.12 - PR Newswire
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Hemispherx Biopharma, Inc.
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Hemispherx Biopharma, Inc. PR Newswire
19.12.12 - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Hemispherx Biopharma, Inc.
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Hemispherx Biopharma, Inc. PR Newswire
27.02.06 - Aktiencheck
Hemispherx hoch spekulativ - Hot Stocks Investor
24.10.05 - Aktiencheck
Hemispherx für mutige Investoren - Hot Stocks Investor
11.04.05 - Aktiencheck
Hemispherx Musterdepotaufnahme - Hot Stocks Investor
04.04.05 - Aktiencheck
Hemispherx Positionen aufbauen - Global Insider Investing
15.10.02 - Aktiencheck
Hemispherx spekulativ kaufen - Global Biotech Investing

Newssuche

Videos

17.05.24 -6,64%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »